Combined umbilical and haploidentical stem cells for allogeneic transplantation – pro

Allogeneic stem cell transplantation is the only curative therapy for several hematologic malignancies, but the inability to identify a suitable HLA-matched donor in a timely manner can preclude the use of this potentially lifesaving procedure. Sequential clinical trials have led to the refinement of successful approaches using alternative donor sources, either combined cord blood units or haploidentical-related family members. Since teh first report several years ago, there is great interest in combining both of these donor sources. There is preliminary evidence that combining cord cells and haploidentical related cells hasten engraftments but there is still not long term survival information and many questions remain. Unfortunately, long term results are not yet known and the procedure is experimental at this time as several large trials are ongoing. One such trial is a two arm phase II protocol, Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies, NCT01682226.

J Chen, R-X Wang, F Chen, A-N Sun, H-Y Qiu, Z-M Jin, X-W Tang, Y Han, Z-Z Fu, G-S He, M Miao, X Ma and D-P Wu. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplantation 49, 206-211 (February 2014)

Yamei Wua et al, Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: Successful engraftment and mild GVHD tem Cell Research. Volume 12, Issue 1, January 2014, Pages 132–138

Categories

Blog Archives